BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$67.94+1.55 (+2.33%)
Close on Oct 19, 2026
- Market cap
- $13.30B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$13.02 (+23.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BridgeBio Pharma, Inc. grew revenue 202.4% to $713.07M over the twelve months to Jun 30, 2026. Free cash flow was -$435.39M.
Revenue
$713.07M
+202.4% vs. a year earlier
Operating income
-$497.80M
TTM Q2 2026
Free cash flow
-$435.39M
TTM Q2 2026
EPS, diluted
-$3.57
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $13.30B
- P/E ratio
- –
- Price to sales
- 18.65
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.27%
Fundamentals
- Revenue
- $713.07M
- EPS, diluted
- -$3.57
- Free cash flow
- -$435.39M
- Book value per share
- -$12.85
- Diluted shares
- 196M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$713.07M+202.4% YoY
Gross profit
$673.41M+196.9% YoY
Operating income
-$497.80M
EPS, diluted
-$3.57
Free cash flow
-$435.39M
Reported periodTrailing twelve months